Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients.
We have recently completed our pivotal trials of envudeucitinib, our second-generation tyk2 inhibitor in moderate to severe plaque psoriasis and expect results from a potentially pivotal Phase 2b trial in SLE in the third quarter of 2026.
As a key member of the Alumis team, you will provide overall leadership for the Medical Affairs function, overseeing Medical Affairs, Field Medical Liaisons, and publications. The position will liaise closely with the clinicians responsible for carrying out Alumis’ clinical studies as well as our commercial group. Applicants should be a “leader/doer” capable of generating strategies and leading cross functionally. This VP, Medical Affairs will report directly to the Chief Medical Officer.
Responsibilities
Lead the Medical Affairs function at Alumis
As a member of the Development Leadership Team, run and continue to build the Medical Affairs function
Education | Experience | Skill Requirements
The salary range for this position is $315,000 USD to $370,000 USD annually. This salary range is an estimate, and the actual salary may vary based on the Company’s compensation practices.
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
Take the next step in your career journey